Here, we describe genetic and immune profiling in a multicenter cohort of patients with RET-rearranged NSCLC, analyze their associations with clinical outcomes, and document treatment outcomes in routine clinical care. The gene discussed is RET; the disease is non-small cell lung carcinoma.